Novartis exploits J&J recall pains with Triaminic giveaway

Share this article:
Novartis exploits J&J recall pains with Triaminic giveaway
Novartis exploits J&J recall pains with Triaminic giveaway
Novartis is capitalizing on rival J&J's woes with a giveaway of its new Triaminic OTC children's acetaminophen.

The company said it would distribute 250,000 bottles of free Triaminic Fever Reducer Pain Reliever, which will compete with children's Tylenol, between August 2nd and August 8th as part of the launch of the line extension. That's $1.5 million worth, said Novartis.

In addition, the company is reaching out to pediatricians, pharmacists and parenting websites “to make them aware that there's a fever reducer pain reliever product now available from a trusted brand,” said Novartis Consumer Health director of communications Julie Maslow, and has deployed 100 reps to provide samples to pediatricians. There are no plans for traditional TV or print advertising, she said.

In April, J&J's McNeil Consumer Healthcare kicked off a snowballing recall of its children's and infants' Tylenol and other OTC brands due to manufacturing problems.

The kick-'em-while-they're-down tactic is a time-honored one in pharma marketing. Earlier in the month, when safety worries hit GlaxoSmithKline's Avandia, Takeda launched an opportunistic consumer advertising effort on behalf of its Actos. Similarly, in 2008, when Merck-Schering-Plough's Vytorin was in the headlines over efficacy doubts, AstraZeneca piled on with ads trumpeting Crestor's virtues.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.